Westfield Capital Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
49.45%
This Fund
S&P 500
1 Year Est. Return
+49.45%
AUM
$23.8B
AUM Growth
-$170M
(-0.71%)
Holding
287
Top Buys
| 1 | +$159M | |
| 2 | +$144M | |
| 3 | +$132M | |
| 4 |
Axon Enterprise
AXON
|
+$121M |
| 5 |
Jones Lang LaSalle
JLL
|
+$112M |
Top Sells
| 1 | +$185M | |
| 2 | +$142M | |
| 3 | +$133M | |
| 4 |
Atlassian
TEAM
|
+$132M |
| 5 |
Revolution Medicines
RVMD
|
+$130M |
Sector Composition
| 1 | Technology | 28.43% |
| 2 | Industrials | 25.27% |
| 3 | Healthcare | 15.8% |
| 4 | Consumer Discretionary | 10.5% |
| 5 | Financials | 8.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CMA
276
DELISTED
Comerica
CMA
| – | – |
-8,560
|
|
||
277
Churchill Downs
CHDN
$6.08B
| – | – |
-4,330
|
|
||
|
CDTX
278
DELISTED
Cidara Therapeutics
CDTX
| – | – |
-1,411
|
|
||
279
Burlington
BURL
$20.4B
| – | – |
-302,307
|
|
||
280
Berkshire Hathaway Class B
BRK.B
$1.02T
| – | – |
-2,350
|
|
||
281
Builders FirstSource
BLDR
$8.2B
| – | – |
-475,697
|
|
||
282
Booking.com
BKNG
$130B
| – | – |
-5,250
|
|
||
283
Bio-Rad Laboratories Class A
BIO
$8.36B
| – | – |
-165,107
|
|
||
284
Beam Therapeutics
BEAM
$3.39B
| – | – |
-8,073
|
|
||
|
BCYC
285
Bicycle Therapeutics
BCYC
$327M
| – | – |
-3,016,026
|
|
||
286
Alkami Technology
ALKT
$1.94B
| – | – |
-4,118,355
|
|
||
287
ADMA Biologics
ADMA
$1.85B
| – | – |
-6,992,907
|
|